Drug-Resistant 'Superbug' Confirmed in 23 States: Should You Worry? Federal health officials have confirmed the spread of a drug-resistant fungal infection called Candida auris across 23 U.S. states, with over 3,000 reported cases in 2026. The Centers for Disease Control and Prevention (CDC) highlighted the growing concern over the pathogen’s resistance to standard antifungal treatments and its potential to spread within healthcare facilities. Texas leads the nation with 706 cases as of July 18, followed by Michigan (503) and Illinois (366). The CDC also noted a steady rise in cases from 2,882 in 2022 to 6,197 in 2024, underscoring the urgency of addressing the outbreak. Experts emphasize that while the general public faces minimal risk, individuals in healthcare settings—particularly those with weakened immune systems or chronic illnesses—are most vulnerable. The CDC reports that 88% of clinic cases involve people aged 45 and older, with the majority of infections occurring in acute care facilities. Candida auris, a type of yeast, can enter the bloodstream and spread systemically, often surviving on surfaces for weeks and transmitting through contaminated medical equipment or person-to-person contact. The fungus has developed resistance to multiple antifungal medications, with some strains becoming entirely untreatable. Susan Huang, a professor of infectious diseases at the University of California Irvine, noted a doubling of positive screening cultures for Candida auris between 2022 and 2024, from 6,000 to 12,000 cases. She described the rapid global emergence and U.S. spread as alarming, urging public awareness.#texas #vanderbilt_university #centers_for_disease_control #university_of_california_irene #university_of_california_san_francisco
